A systematic evaluation of immunoassay point-of-care testing to define impact on patients' outcomes
Related Experiment Video
Updated: Mar 8, 2026

Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
Published on: March 22, 2022
Valentina Pecoraro1,2, Giuseppe Banfi3,4, Luca Germagnoli5
11 Department of Laboratory Medicine, Clinical Pathology-Toxicology, Ospedale Civile Sant'Agostino Estense, Modena, Italy.
Insights
Point-of-care testing (POCT) immunoassays for troponin, brain natriuretic peptide, and C-reactive protein show reliable analytical performance and accuracy. While POCT offers rapid results, its impact on patient outcomes requires further investigation.
Area of Science:
- Clinical Chemistry
- Diagnostic Accuracy
- Point-of-Care Testing
Background:
- Point-of-care testing (POCT) aims to expedite diagnostic results, but research often overlooks its clinical utility.
- Most studies focus on analytical performance rather than patient outcome impact.
Purpose of the Study:
- To review the analytical performance and accuracy of POCT immunoassays.
- To evaluate the impact of rapid POCT results on patient management and clinical decisions.
Main Methods:
- Systematic review of 116 scientific papers comparing POCT immunoassay results with central laboratory findings.
- Evaluation of analytical characteristics and diagnostic accuracy for troponin, procalcitonin, parathyroid hormone, brain natriuretic peptide, C-reactive protein, and neutrophil gelatinase-associated lipocalin.
Main Results:
- Satisfactory analytical correlations between POCT and central laboratory results were reported in 44% of studies.
- Diagnostic accuracy was acceptable for troponin, brain natriuretic peptide, and C-reactive protein.
- Limited impact on diagnostic decisions was noted for procalcitonin, parathyroid hormone, and neutrophil gelatinase-associated lipocalin; C-reactive protein showed reduced antibiotic prescriptions.
Conclusions:
- POCT immunoassays for troponin, brain natriuretic peptide, and C-reactive protein demonstrate reliable and accurate performance.
- POCT offers excellent practicability and could be a valuable clinical tool.
- More research is needed to establish the definitive impact of POCT on patient outcomes.
Abstract:
Background Point-of-care testing has been developed to provide rapid test results. Most published studies focus on analytical performance, neglecting its impact on patient outcomes. Objective To review the analytical performance and accuracy of point-of-care testing specifically planned for immunoassay and to evaluate the impact of faster results on patient management. Methods A search of electronic databases for studies reporting immunoassay results obtained in both point-of-care testing and central laboratory scenarios was performed. Data were extracted concerning the study details, and the methodological quality was assessed. The analytical characteristics and diagnostic accuracy of six points-of-care testing: troponin, procalcitonin, parathyroid hormone, brain natriuretic peptide, C-reactive protein and neutrophil gelatinase-associated lipocalin were evaluated. Results A total of 116 scientific papers were analysed. Studies measuring procalcitonin, parathyroid hormone and neutrophil gelatinase-associated lipocalin reported a limited impact on diagnostic decisions. Seven studies measuring C-reactive protein claimed a significant reduction of antibiotic prescription. Several authors evaluated brain natriuretic peptide or troponin reporting faster decision-making without any improvement in clinical outcome. Forty-four per cent of studies reported analytical data, showing satisfactory correlations between results obtained through point-of-care testing and central laboratory setting. Half of studies defined the diagnostic accuracy of point-of-care testing as acceptable for troponin (median sensitivity and specificity: 74% and 94%, respectively), brain natriuretic peptide (median sensitivity and specificity: 82% and 88%, respectively) and C-reactive protein (median sensitivity and specificity 85%). Conclusions Point-of-care testing immunoassay results seem to be reliable and accurate for troponin, brain natriuretic peptide and C-reactive protein. The satisfactory analytical performance, together with an excellent practicability, suggests that it could be a consistent tool in clinical practice, but data are lacking regarding the patient outcomes.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
10:16Author Spotlight: Development of Simplified CRISPR-Based Tests for Rapid Detection of Infectious Diseases
Published on: August 16, 2024